Twin Lakes Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

Twin Lakes Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-416	Closed	-$778	–	262
2023 Q2	$778	Sell	416 -1	-0.2%	-$4	﹤0.01%	238
2023 Q1	$1.56K	Hold	417	–	–	﹤0.01%	236
2022 Q4	$1.29K	Hold	417	–	–	﹤0.01%	236
2022 Q3	$2K	Buy	+417	New	+$4.13K	﹤0.01%	244
2022 Q2	–	Sell	-3,150	Closed	-$117K	–	284
2022 Q1	$117K	Hold	3,150	–	–	0.07%	109
2021 Q4	$184K	Hold	3,150	–	–	0.1%	101
2021 Q3	$259K	Buy	+3,150	New	+$274K	0.15%	78

Other funds holding VTGN

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Twin Lakes Capital Management's VTGN Position: Q3 2023 in Review

Twin Lakes Capital Management sold out of VistaGen Therapeutics (VTGN) in Q3 2023, closing a stake of 416 shares — an estimated $778 sold.

Twin Lakes Capital Management first reported a position in VTGN in Q3 2021 and held it in 7 quarters. The position peaked at $259K in Q3 2021. 34 funds tracked by Wall St. Rank hold VTGN as of Q3 2023.

Twin Lakes Capital Management reported no remaining VistaGen Therapeutics position as of Q3 2023 after selling out during the quarter.
Twin Lakes Capital Management sold 416 VistaGen Therapeutics shares in Q3 2023, an estimated $778.
Twin Lakes Capital Management first reported a position in VistaGen Therapeutics in Q3 2021 and held it in 7 quarters.
Twin Lakes Capital Management's VistaGen Therapeutics position peaked at $259K in Q3 2021.
34 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2023.

Based on Twin Lakes Capital Management's 13F filing for Q3 2023, filed 16 Nov 2023.